Steven Dubois, MD
Enriched profileDirector of Experimental Therapeutics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center · Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Harvard Medical School
Steven Dubois is Director of Experimental Therapeutics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center at Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Harvard Medical School. OpenAlex indexes 544 publications with 18,621 citations (h-index 66); ClinicalTrials.gov lists 15 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 13 Oct 2026
Overview
Updated 13 Oct 2026
Steven Dubois, M.D., is Director of Experimental Therapeutics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center. The public record shows 544 publications with 18,621 citations (h-index 66), centered on Sarcoma Diagnosis and Treatment, Neuroblastoma Research and Treatments, Acute Lymphoblastic Leukemia research. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 5 companies, 3 NIH-funded awards (2015–2023).
- Most recent indexed publication: 2026 · Pediatric blood & cancer
- Top research focus: Sarcoma Diagnosis and Treatment
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 80 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 213.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Oct 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- Lurbinectedin in FET-Fused Tumors
Sponsor: Children's Hospital of Philadelphia
- CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Sponsor: Children's Oncology Group
Industry payments
Updated 13 Oct 2026
5 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20252 payments
- EMD Serono Research & Development Institute, Inc.Program year20241 payment
- JAZZ PHARMACEUTICALS INC.Program year20221 payment
NIH funding
Updated 13 Oct 2026
3 NIH research awards on record, funded 2015–2023 per NIH RePORTER. The latest:
- Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma
Dana-Farber Cancer Inst
FY2023$347,922R01CA214912 - Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma
Dana-Farber Cancer Inst
FY2021$594,506R01CA214912 - Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma
Dana-Farber Cancer Inst
FY2020$310,299R01CA214912
Congress activity
Updated 13 Oct 2026
126 congress contributions (2007–2026) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract A029: Larotrectinib long-term efficacy and safety in pediatric patients with TRK fusion non-primary CNS tumors: Analysis update
AACR (meeting unresolved)
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 13 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Access to Anticancer Drug Trials for Adolescents With Cancer in the United States.
Pediatric blood & cancer
Article2026 - Factors Impacting Overall Survival Post-Relapse in High-Risk Neuroblastoma: Children's Oncology Group Outcomes From 2000 to 2019.
Pediatric blood & cancer
Article2026 - Long-Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group.
Pediatric blood & cancer
Article2026 - A First-in-Pediatric Study of ALRN-6924, a Novel Stapled-Peptide Dual MDM2/MDMX Inhibitor, for Children with Advanced Hematologic and Solid Malignancies.
Clinical cancer research
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and ChildrenArticle2,801 citations2018
- 02
- 03
- 04
- 05
Network
Updated 13 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 13 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
thekidscancerproject.org.au/steve-dubois-rac
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thekidscancerproject.org.au ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- MD
University of California, San Francisco School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thekidscancerproject.org.au ↗
- Member
American Pediatric Society
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Awards & honors
honors on the public record- Top Doctor Award2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliations
appointments beyond the home institution- Scientific Advisory Board
Alex's Lemonade Stand Foundation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alexslemonade.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alexslemonade.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
George Demetri, MD
Dana-Farber Cancer Institute; Professor of Medicine
Richard Gorlick, MD
The University of Texas MD Anderson Cancer Center
William Tap, MD
Memorial Sloan Kettering Cancer Center
Scott Schuetze, MD
University of Michigan Medical School